HA-RAS RARE ALLELES IN MALIGNANT GLIOMA

恶性胶质瘤是脑内最常见的原发性恶性肿瘤， 成年人，是衰弱和迅速致命的。 很少有人知道 其原因;家族史和各种环境因素已被 在流行病学研究中提出， 在分子生物学研究中。 我们目前正在进行一个大型的， 美国国家癌症研究所资助的一项基于人群的恶性胶质瘤流行病学研究 在旧金山弗朗西斯科湾区， 病史，职业，吸烟，饮酒，饮食， 电磁场暴露和其他特征， 对照 我们正在对病例和年龄进行详细的访谈， 性别和种族匹配的对照组。 然而，目前没有资金 用于血液收集或用于基因型测定， 致癌基因 这笔小额赠款的一个主要目的是收集、处理、 储存300个恶性神经胶质瘤病例的血液样本 和300个对照，以使这些受试者的分子遗传学研究， 候选基因被识别。 因为最常见的 恶性胶质瘤是迅速致命的，我们将无法从 这些案件在未来;因此，有时间限制的访问案件， 本研究 这笔小额赠款的其他目的是： 病例和对照的基因型;测试罕见的Ha-ras等位基因是否 更常见的情况下，因为他们在以前发表的研究; 使用在Ha-ras上收集的信息作为模型， 为评价候选人拟订一项全面的建议 基因. 一个有经验的抽血者将收集血液从愿意 科目 将使用标准方法制备基因组DNA样本 从白色血细胞中提取，并进行Southern印迹研究以确定 Ha-ras基因型。 我们将有足够的力量 检测罕见Ha-ras VTR比例的有意义差异 病例和对照的等位基因。 除了基因数据， 将使用收集的关于受试者其他特征的信息 探讨这些因素中是否有任何一个改变了Ha-ras基因与 VTR罕见等位基因与恶性胶质瘤 这项研究将是第一个 联合收割机对患有和不患有恶性胶质瘤的个体进行基因分型， 关于流行病学上一个可疑的易感基因， 明确的基于人群的研究。 因此，它将作为一个试点 对其他易感基因进行更全面评估的研究 恶性神经胶质瘤

Malignant glioma, the most common primary malignant brain tumor in adults, is debilitating and rapidly fatal. Very little is known about its causes; family history and diverse environmental factors have been suggested in epidemiologic studies and several genes have been implicated in molecular biology studies. We are currently conducting a large, NCI-funded, population-based epidemiologic study of malignant glioma in the San Francisco Bay Area to examine and compare family and personal medical histories, occupation, smoking, alcohol use, diet, electromagnetic field exposures and other characteristics in cases and controls. We are conducting detailed interviews with cases and age-, sex-, and race-matched controls. However, there is currently no funding for blood collection or for genotype determination for pertinent oncogenes. A major purpose of this small grant is to collect, process, and store blood samples from 300 malignant glioma cases as we accrue them and 300 controls to enable molecular genetic studies of these subjects as candidate genes become identified. Because the most common form of malignant glioma is rapidly fatal, we would be unable to draw blood from these cases in the future; thus, there is time-limited access to cases in this study. Additional aims of this small grant are to: determine Ha-ras genotypes of cases and controls; test whether rare Ha-ras alleles are more common in cases, as they were in one previously published study; and use the information collected on Ha-ras to serve as a model for developing a comprehensive proposal for the evaluation of candidate genes. An experienced phlebotomist will collect blood from willing subjects. Standard methods will be used to prepare genomic DNA samples from white blood cells and to conduct Southern blot studies to determine the Ha-ras genotypes in these samples. We will have adequate power to detect meaningful differences in the proportion of rare Ha-ras VTR alleles in cases and controls. In addition to the genetic data, information collected on other characteristics of subjects will be used to explore whether any of these factors modify the association of Ha-ras VTR rare alleles with malignant glioma. This study will be the first to combine genotyping of individuals with and without malignant glioma with regard to one suspected susceptibility gene in an epidemiologically well-defined population-based study. It will therefore serve as a pilot study for a more comprehensive evaluation of other susceptibility genes for malignant glioma.